Insider Buying: Bolt Biotherapeutics (NASDAQ:BOLT) Major Shareholder Acquires 20,000 Shares of Company Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) major shareholder Coastlands Capital Lp bought 20,000 shares of the firm’s stock in a transaction dated Tuesday, November 17th. The shares were purchased at an average price of $5.75 per share, with a total value of $115,000.00. Following the acquisition, the insider directly owned 515,510 shares in the company, valued at approximately $2,964,182.50. This trade represents a 4.04% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Coastlands Capital Lp also recently made the following trade(s):

  • On Monday, November 16th, Coastlands Capital Lp bought 33,094 shares of Bolt Biotherapeutics stock. The shares were acquired at an average cost of $5.89 per share, with a total value of $194,923.66.
  • On Monday, November 9th, Coastlands Capital Lp purchased 50,000 shares of Bolt Biotherapeutics stock. The stock was acquired at an average price of $6.38 per share, for a total transaction of $319,000.00.

Bolt Biotherapeutics Trading Down 2.6%

NASDAQ BOLT traded down $0.15 during mid-day trading on Tuesday, hitting $5.65. The company’s stock had a trading volume of 86,613 shares, compared to its average volume of 752,022. Bolt Biotherapeutics, Inc. has a 52-week low of $3.10 and a 52-week high of $7.78. The stock’s fifty day simple moving average is $4.70 and its two-hundred day simple moving average is $4.51. The company has a debt-to-equity ratio of 2.06, a current ratio of 2.05 and a quick ratio of 2.61. The firm has a market capitalization of $14.75 million, a P/E ratio of -0.38 and a beta of 0.85.

Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($2.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.68) by $1.43. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 154.11%. The firm had revenue of $0.45 million for the quarter, compared to analysts’ expectations of $0.45 million. Research analysts expect that Bolt Biotherapeutics, Inc. will post -11.10 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Bolt Biotherapeutics stock. Renaissance Technologies LLC grew its stake in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Report) by 40.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 77,225 shares of the company’s stock after purchasing an additional 22,200 shares during the quarter. Renaissance Technologies LLC owned 4.02% of Bolt Biotherapeutics worth $312,000 at the end of the most recent quarter. 86.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $14.50.

Get Our Latest Stock Analysis on Bolt Biotherapeutics

Bolt Biotherapeutics Company Profile

(Get Free Report)

Bolt Biotherapeutics is a clinical-stage biotechnology company based in Redwood City, California. It develops immunotherapies designed to direct the body’s immune system against cancer. The company’s Boltbody platform is designed to pair tumor-targeting antibodies with immune-stimulating components. Its pipeline has included BDC-3042, an investigational antibody intended to activate macrophages, immune cells that can help recognize and attack tumors. Bolt has also developed BDC-1001, an investigational HER2-targeting immune-stimulating antibody conjugate.

Featured Stories

Insider Buying and Selling by Quarter for Bolt Biotherapeutics (NASDAQ:BOLT)

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.